| NRF2 and the Hallmarks of Cancer |
157 |
| Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer |
156 |
| Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer |
148 |
| T Cell Dysfunction in Cancer |
137 |
| Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer |
130 |
| The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy |
117 |
| Comprehensive Analysis of Alternative Splicing Across Tumors from 705 Patients |
104 |
| Genomic and Functional Approaches to Understanding Cancer Aneuploidy |
100 |
| lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer |
96 |
| The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers |
96 |
| Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer |
95 |
| Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets |
94 |
| The Intestinal Microbiota in Colorectal Cancer |
85 |
| Targeting Ferroptosis to Iron Out Cancer |
83 |
| Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress |
83 |
| Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies |
80 |
| A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers |
76 |
| Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies |
73 |
| Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance |
73 |
| Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy |
68 |
| Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas |
67 |
| BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines |
65 |
| Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies |
62 |
| KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer |
59 |
| Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1 |
57 |
| The Platelet Lifeline to Cancer: Challenges and Opportunities |
56 |
| Transcriptional Regulation of the Warburg Effect in Cancer by SIX1 |
55 |
| Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia |
55 |
| Notch Signaling in the Tumor Microenvironment |
54 |
| Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors |
52 |
| A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo |
51 |
| Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells |
49 |
| Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer |
48 |
| Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway |
48 |
| An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer |
46 |
| Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells |
46 |
| The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients |
46 |
| CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought |
45 |
| The Immune Revolution: A Case for Priming, Not Checkpoint |
44 |
| Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies |
43 |
| Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? |
43 |
| Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis |
41 |
| Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy |
41 |
| Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring Kynurenine and AhR Activation |
40 |
| Biological Role and Therapeutic Potential of IDH Mutations in Cancer |
39 |
| TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer |
39 |
| Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting |
39 |
| BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency |
38 |
| beta 2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer |
38 |
| ORY- a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia |
37 |
| Hacking the Cancer Genome: Profiling Therapeutically Actionable Long Non-coding RNAs Using CRISPR-Cas9 Screening |
37 |
| A Convergence-Based Framework for Cancer Drug Resistance |
37 |
| CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response |
37 |
| Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis |
37 |
| Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression |
37 |
| Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors |
36 |
| Cytosolic DNA Sensing in Organismal Tumor Control |
36 |
| Mutant NPM1 Maintains the Leukemic State through HOX Expression |
35 |
| Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors |
35 |
| Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia |
35 |
| RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis |
35 |
| Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality |
34 |
| A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia |
34 |
| The Integrated Genomic Landscape of Thymic Epithelial Tumors |
34 |
| Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion |
34 |
| Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes |
34 |
| Systematic Functional Annotation of Somatic Mutations in Cancer |
33 |
| Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance |
32 |
| Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling |
31 |
| Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis |
31 |
| Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation |
30 |
| Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers |
30 |
| Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors |
30 |
| SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis |
30 |
| A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment |
30 |
| The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma |
29 |
| Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories |
29 |
| Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation |
29 |
| Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines |
29 |
| Proteogenomic Characterization of Human Early-Onset Gastric Cancer |
29 |
| An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles |
28 |
| Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly |
28 |
| Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers |
28 |
| Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial |
28 |
| Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma |
28 |
| Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy |
28 |
| Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment |
28 |
| Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hurthle Cell Carcinoma |
28 |
| Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality |
28 |
| Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer |
28 |
| Non-conventional Inhibitory CD4(+)Foxp3(-)PD-1(hi) T Cells as a Biomarker of Immune Checkpoint Blockade Activity |
28 |
| Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms |
27 |
| Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer |
27 |
| Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer |
27 |
| Adenosine Metabolism: Emerging Concepts for Cancer Therapy |
27 |
| Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations |
27 |
| Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling |
26 |
| RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer |
26 |
| KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism |
26 |
| The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma |
26 |
| Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations |
26 |
| Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3 beta-MCL-1 Axis |
25 |
| Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase |
25 |
| Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development |
25 |
| The Proteogenomic Landscape of Curable Prostate Cancer |
25 |
| Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG |
25 |
| A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK |
25 |
| Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes |
25 |
| Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA |
24 |
| Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization |
24 |
| Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants |
24 |
| Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis |
24 |
| Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases |
24 |
| Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia |
24 |
| Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma |
24 |
| Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling |
23 |
| Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants |
23 |
| Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia |
23 |
| Increased Serine and One-Carbon Pathway Metabolism by PKC lambda/l Deficiency Promotes Neuroendocrine Prostate Cancer |
23 |
| ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer |
23 |
| PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth |
22 |
| Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity |
22 |
| EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation |
22 |
| Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging |
22 |
| Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells |
22 |
| Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups |
21 |
| A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor |
21 |
| Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution |
21 |
| PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells |
21 |
| A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer |
21 |
| PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8(+) T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients |
20 |
| Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations |
20 |
| Anti-tumor Activity of the Type I PRMT Inhibitor, GSK336 Synergizes with PRMT5 Inhibition through MTAP Loss |
20 |
| Passenger Hotspot Mutations in Cancer |
20 |
| EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma |
20 |
| The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression |
20 |
| Th9 Cells Represent a Unique Subset of CD4(+) T Cells Endowed with the Ability to Eradicate Advanced Tumors |
20 |
| The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability |
19 |
| Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy |
19 |
| Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor |
19 |
| The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils |
18 |
| UTX Mutations in Human Cancer |
18 |
| KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance |
18 |
| Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation |
18 |
| Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors |
18 |
| Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis |
18 |
| Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma |
18 |
| Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas |
18 |
| Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS |
17 |
| Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype |
17 |
| Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting |
17 |
| Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair |
17 |
| Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies |
17 |
| Cellular Pliancy and the Multistep Process of Tumorigenesis |
17 |
| Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation |
17 |
| Targeting p38 alpha Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells |
16 |
| Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy |
16 |
| Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer |
16 |
| HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice |
16 |
| A Pharmacogenomic Landscape in Human Liver Cancers |
16 |
| Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones |
16 |
| Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity |
16 |
| The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations |
16 |
| Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation |
16 |
| HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis |
15 |
| Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence |
15 |
| p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors |
15 |
| RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance |
15 |
| MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis |
15 |
| Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8(+)T Cells |
15 |
| The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters |
15 |
| DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns |
14 |
| Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and Braf(V600E)- Induced Tumorigenesis |
14 |
| Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias |
14 |
| Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways |
14 |
| Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells |
14 |
| Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses |
14 |
| Disruption of the beta 1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner |
14 |
| The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma |
13 |
| Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia |
13 |
| Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties |
13 |
| DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors |
13 |
| Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation |
13 |
| p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors |
12 |
| Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer |
12 |
| Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia |
12 |
| Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF |
12 |
| Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity |
12 |
| Selective Fc gamma R Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens |
12 |
| The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation |
11 |
| MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation |
11 |
| The Fire within: Cell-Autonomous Mechanisms in Inflammation-Driven Cancer |
11 |
| Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies |
11 |
| A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion |
11 |
| Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8(+) T Cell Apoptosis |
11 |
| DNA Methylation Patterns Separate Senescence from Transformation Potential and Indicate Cancer Risk |
11 |
| The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease |
11 |
| Molecular Signatures of Regression of the Canine Transmissible Venereal Tumor |
10 |
| Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis |
10 |
| Real-Time Molecular Diagnosis of Tumors Using Water-Assisted Laser Desorption/lonization Mass Spectrometry Technology |
10 |
